MedTrace Logo

AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL

NCT07215585 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2026-05-22

No results posted yet for this study

Summary

The purpose of this study is to measure the efficacy and safety of R-mini-CHOP × 2 followed by AZD0486 compared with R-mini-CHOP × 6 in elderly or unfit participants newly diagnosed with LBCL.

Conditions

Interventions

DRUG

AZD0486

Bispecific monoclonal IgG4 antibody

DRUG

R-mini-CHOP

Intravenous administration: Rituximab 375 mg/m2, Cyclophosphamide 400 mg/m2, Doxorubicin 25 mg/m2, Vincristine 1 mg, and Oral administration: Prednisone 40 mg/m2

Sponsors & Collaborators

Principal Investigators

  • Michael Dickinson,, MBBS BS DMSc · Peter MacCallum Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-11
Primary Completion
2030-06-10
Completion
2033-07-28
FDA Drug
Yes

Countries

  • Australia
  • Belgium
  • Brazil
  • Canada
  • China
  • Hong Kong
  • Japan
  • Poland
  • South Korea
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07215585 on ClinicalTrials.gov